Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Clinical significance of microRNA-148a in patients with early relapse of stage II stage and III colorectal cancer after curative resection.

Tsai HL, Yang IP, Huang CW, Ma CJ, Kuo CH, Lu CY, Juo SH, Wang JY.

Transl Res. 2013 Oct;162(4):258-68. doi: 10.1016/j.trsl.2013.07.009. Epub 2013 Aug 7.

PMID:
23933284
2.

The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse.

Yang IP, Tsai HL, Huang CW, Huang MY, Hou MF, Juo SH, Wang JY.

PLoS One. 2013 Jun 28;8(6):e66842. doi: 10.1371/journal.pone.0066842. Print 2013.

3.

MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle.

Yang IP, Tsai HL, Hou MF, Chen KC, Tsai PC, Huang SW, Chou WW, Wang JY, Juo SH.

Carcinogenesis. 2012 Aug;33(8):1522-30. doi: 10.1093/carcin/bgs166. Epub 2012 May 10.

PMID:
22581829
4.

Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.

Uen YH, Lin SR, Wu DC, Su YC, Wu JY, Cheng TL, Chi CW, Wang JY.

Ann Surg. 2007 Dec;246(6):1040-6.

PMID:
18043108
5.

Predictive factors of early relapse in UICC stage I-III colorectal cancer patients after curative resection.

Tsai HL, Chu KS, Huang YH, Su YC, Wu JY, Kuo CH, Chen CW, Wang JY.

J Surg Oncol. 2009 Dec 15;100(8):736-43. doi: 10.1002/jso.21404.

PMID:
19757443
6.

The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer.

Takahashi M, Cuatrecasas M, Balaguer F, Hur K, Toiyama Y, Castells A, Boland CR, Goel A.

PLoS One. 2012;7(10):e46684. doi: 10.1371/journal.pone.0046684. Epub 2012 Oct 3.

7.

Development of a deregulating microRNA panel for the detection of early relapse in postoperative colorectal cancer patients.

Yang IP, Tsai HL, Miao ZF, Huang CW, Kuo CH, Wu JY, Wang WM, Juo SH, Wang JY.

J Transl Med. 2016 Apr 29;14(1):108. doi: 10.1186/s12967-016-0856-2.

8.

miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.

Gao J, Li N, Dong Y, Li S, Xu L, Li X, Li Y, Li Z, Ng SS, Sung JJ, Shen L, Yu J.

Oncogene. 2015 Jul 30;34(31):4142-52. doi: 10.1038/onc.2014.348. Epub 2014 Nov 3.

PMID:
25362853
9.
10.

Genetic and epigenetic down-regulation of microRNA-212 promotes colorectal tumor metastasis via dysregulation of MnSOD.

Meng X, Wu J, Pan C, Wang H, Ying X, Zhou Y, Yu H, Zuo Y, Pan Z, Liu RY, Huang W.

Gastroenterology. 2013 Aug;145(2):426-36.e1-6. doi: 10.1053/j.gastro.2013.04.004. Epub 2013 Apr 9.

PMID:
23583431
11.

Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice.

Yuan K, Xie K, Fox J, Zeng H, Gao H, Huang C, Wu M.

Gastroenterology. 2013 Oct;145(4):853-64.e9. doi: 10.1053/j.gastro.2013.06.008. Epub 2013 Jun 13.

12.

microRNA-182 targets special AT-rich sequence-binding protein 2 to promote colorectal cancer proliferation and metastasis.

Yang MH, Yu J, Jiang DM, Li WL, Wang S, Ding YQ.

J Transl Med. 2014 May 1;12:109. doi: 10.1186/1479-5876-12-109.

13.

Prognostic significance of PDCD4 expression and association with microRNA-21 in each Dukes' stage of colorectal cancer patients.

Horiuchi A, Iinuma H, Akahane T, Shimada R, Watanabe T.

Oncol Rep. 2012 May;27(5):1384-92. doi: 10.3892/or.2012.1648. Epub 2012 Jan 19.

PMID:
22267128
14.

Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer.

Weissmann-Brenner A, Kushnir M, Lithwick Yanai G, Aharonov R, Gibori H, Purim O, Kundel Y, Morgenstern S, Halperin M, Niv Y, Brenner B.

Int J Oncol. 2012 Jun;40(6):2097-103. doi: 10.3892/ijo.2012.1403. Epub 2012 Mar 16.

PMID:
22426940
15.

Significance of miR-148a in Colorectal Neoplasia: Downregulation of miR-148a Contributes to the Carcinogenesis and Cell Invasion of Colorectal Cancer.

Hibino Y, Sakamoto N, Naito Y, Goto K, Oo HZ, Sentani K, Hinoi T, Ohdan H, Oue N, Yasui W.

Pathobiology. 2015;82(5):233-41. doi: 10.1159/000438826. Epub 2015 Sep 22.

PMID:
26389729
16.

Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection.

Uen YH, Lu CY, Tsai HL, Yu FJ, Huang MY, Cheng TL, Lin SR, Wang JY.

Ann Surg Oncol. 2008 Aug;15(8):2120-8. doi: 10.1245/s10434-008-9961-7. Epub 2008 May 15.

PMID:
18481151
17.

Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer.

Goh CH, Leong WQ, Chew MH, Pan YS, Tony LK, Chew L, Tan IB, Toh HC, Tang CL, Fu WP, Chia WK.

Anticancer Res. 2014 Dec;34(12):7407-14. Erratum in: Anticancer Res. 2015 Feb;35(2):1219. Goh, Hin Hock [corrected to Goh, Chin Hock].

PMID:
25503181
18.

MicroRNA-31 contributes to colorectal cancer development by targeting factor inhibiting HIF-1α (FIH-1).

Chen T, Yao LQ, Shi Q, Ren Z, Ye LC, Xu JM, Zhou PH, Zhong YS.

Cancer Biol Ther. 2014 May;15(5):516-23. doi: 10.4161/cbt.28017. Epub 2014 Feb 12.

19.

Prognostic significance of preoperative bowel obstruction in stage III colorectal cancer.

Katoh H, Yamashita K, Wang G, Sato T, Nakamura T, Watanabe M.

Ann Surg Oncol. 2011 Sep;18(9):2432-41. doi: 10.1245/s10434-011-1625-3. Epub 2011 Mar 3.

PMID:
21369738
20.

MiR-320e is a novel prognostic biomarker in colorectal cancer.

Perez-Carbonell L, Sinicrope FA, Alberts SR, Oberg AL, Balaguer F, Castells A, Boland CR, Goel A.

Br J Cancer. 2015 Jun 30;113(1):83-90. doi: 10.1038/bjc.2015.168. Epub 2015 Jun 2.

Supplemental Content

Support Center